This is a great point and again shows the Guiding Hand to our efforts.. It is hard to let go sometimes and I think the loss of any Combo Patent made diving harder(Ariana) into the data more vital. They dropped Combo because of its lack of comparative success to A2-73 MonoTherapy.
My guess is Combo would still be on the table as SOC IF Monotherapy was not proving a major significant difference. They would still be exploring both! Why aren't they?
Not because of the failure to Patent Combo, but Mono Data is too robust to deny . What that looks like on a poster board at CTAD .. well we will find out..
Not our last chance on Mono at 41 Weeks? How about Parkinson's? How about all Depressive \ Anxiety indications? How about our 4 other drugs in development that all show promise? We have a platform to develop new drugs as good as or better than the ones we already have! The Combo Patent had some value as to length of non competitive marketing Anavex might enjoy,,but the computer models showing greater effect were just wrong. Whatever we have lost w Combo we gain 100 fold by replacing Aricept.. It's why we have buyers and sellers. Sell. Thank You very much
I disagree with you. Anavex has several indications besides 2-73. This is not our last chance or last stop. parkinson, Rhett, Dementia, etc,.. . Try not being so negative.
Market Data 
Markets 
AI
